Remziye Zaim

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer.

Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer.

Journal: Journal of cancer policy

Published: September 19, 2022

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer.

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer.

Journal: Frontiers in oncology

Published: September 12, 2022

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment.

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment.

Journal: Frontiers in health services

Published: September 01, 2022

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer.

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer.

Journal: Translational oncology

Published: March 29, 2022

Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.

Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.

Journal: Journal of cancer policy

Published: March 16, 2022

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.

Journal: The European journal of health economics : HEPAC : health economics in prevention and care

Published: February 22, 2019

Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.

Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.

Journal: Health technology assessment (Winchester, England)

Published: June 24, 2017

Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance.

Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance.

Journal: BMC medicine

Published: April 27, 2017

Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.

Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.

Journal: Journal of gastroenterology and hepatology

Published: November 30, 2015

'DE NOVO' Quantification of Genotype-Directed Therapy with Afatinib in Metastatic Lung Cancer.

'DE NOVO' Quantification of Genotype-Directed Therapy with Afatinib in Metastatic Lung Cancer.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 01, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026